Harnessing Antisense & RNA Chemistry to Target Undruggable CNS Diseases

2024 EVENT GUIDE
PARTNER WITH US

Thank you to our speakers, sponsors, and delegates who joined us at the 4th Oligonucleotides for CNS Summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com

Heralding a New Era of CNS-Targeted Oligonucleotides to the Clinic and Beyond

Uniting CNS Biotech & Pharma to Fuel the Next Wave of Oligonucleotide Drug Discovery, Translation & Clinical Progress

With Biogen’s milestone approval of Tofersen leading the charge with a first-in-class clinically effective ASO for ALS, the glass ceiling of efficacious and safe oligonucleotides for CNS indications has truly been shattered

The 4th Oligonucleotides for CNS Summit is the only forum wholly dedicated to unique challenges and neuroscience innovation for this modality, delving into the hottest ASO, siRNA, saRNA, and miRNA program updates and the latest industry challenges.

This July, join 150+ senior industry leaders across discovery biology, structural chemistry, preclinical, clinical, CMC, and regulatory this year from Roche, IONIS, Janssen, Merck, Novartis, Genentech, Creyon Bio, Stoke Therapeutics, Dyne Therapeutics and many more….

World-Class Speaker Faculty Included:

David Eyerman

Vice President - Translational Neurology

Apellis Pharmaceuticals

Eloise Hudry headshot

Eloise Hudry

Director

Novartis AG

Evan Mizerak headshot

Evan Mizerak

Lead of Preclinical Research

Amylyx Pharmaceuticals Corp.

Nicholas Yoder headshot

Nicholas Yoder

Executive Director, Platform Development

Dyne Therapeutics

Patirica Sanwald Ducray Headshot

Patricia Sanwald Ducray

Distinguished Scientist, Clinical Pharmacology

Roche

Swagatam Mukhopadhyay

CSO and co-founder

Creyon Bio

2024 Partners Included:

ChemGenes logo
SynOligo Biotechnologies, Oligonucleotides for CNS
Atuka, 4th Oligonucleotides for CNS Summit 2024
PARTNER WITH US

Top Testimonials:

‘Highly focused event with the key issues, representation by the KOLs and companies in the field. Small size facilitated networking.’

Senior Director Translational Medicine, Acadia Pharmaceuticals

‘You’ll meet with experts in the field and learn a lot from them.’

- Associate Director, Alnylam

‘Small meeting allowing for great interactions, but at the same time with most key players in the field.’

Preclinical Research Scientist, Servier

The topics of discussion were very focused and all the attendees were very engaged in the discussion. It was a great experience speaking at the conference and learn from others.’

- Senior Vice President, Stoke Therapeutics

'Extremely informative talks.’

- Co-Founder, Chief Technology Officer, Switch Therapeutics

Other Events in the World CNS Series:

EVENT GUIDE
PARTNER WITH US